Cas:303010-12-0 3-Chloro-6-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]pyridazine manufacturer & supplier

Chemical Name:3-Chloro-6-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]pyridazine

CAS.NO:303010-12-0

Synonyms:Pyridazine,3-chloro-6-[(2,3-dihydro-7-methyl-1H-inden-4-yl)oxy]

Molecular Formula:C₁₄H₁₃ClN₂O

Molecular Weight:260.71900

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:35.01000

Exact Mass:260.07200

LogP:3.71940

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Pyridazine,3-chloro-6-[(2,3-dihydro-7-methyl-1H-inden-4-yl)oxy] chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Pyridazine,3-chloro-6-[(2,3-dihydro-7-methyl-1H-inden-4-yl)oxy] physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Pyridazine,3-chloro-6-[(2,3-dihydro-7-methyl-1H-inden-4-yl)oxy] Use and application,Pyridazine,3-chloro-6-[(2,3-dihydro-7-methyl-1H-inden-4-yl)oxy] technical grade,usp/ep/jp grade.

Related News: The Company��s immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. 3-Chloro-6-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]pyridazine manufacturer Biogen has said that some 1.5 million Americans with early-stage Alzheimer’s will be eligible for the drug, priced at an average of $56,000 per year, with the federal Medicare insurance program for seniors likely on the hook for most of the cost. 3-Chloro-6-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]pyridazine supplier This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment, Mankind Pharma Director of Marketing Sanjay Koul said in a statement. 3-Chloro-6-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]pyridazine vendor Retrogenix��s proprietary cell microarray technology provides a fast, accurate and effective solution for determining the primary target and secondary target (off-target) activities of antibodies, proteins, cell therapies, small molecules and viruses. 3-Chloro-6-[(7-methyl-2,3-dihydro-1H-inden-4-yl)oxy]pyridazine factory On the basis of achieving low-cost and high-quality processes, production capacity will become the core driving force for API companies to break through sales bottlenecks.